Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10517136 | 0.88 | ALDH1A1 (0.64) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3102333 | 0.86 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL28139604 | 0.84 | ALDH1A1 (0.64) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL381400 | 0.84 | ALDH1A1 (0.64) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL29742792 | 0.84 | ALDH1A1 (0.64) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3978878 | 0.82 | NPC1 (0.61) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3914342 | 0.82 | NPC1 (0.61) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL29859324 | 0.82 | TARBP2 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3932665 | 0.82 | GPR35 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL557753 | 0.82 | NPC1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3549930-B1 | NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED | UNIV HIROSHIMA (JP) | 2023-07-19 | — | — | EP | disclosed |
| EP-3549930-B1 | NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED | UNIV HIROSHIMA (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | HIROSHIMA UNIVERSITY (JP) | 2021-12-21 | — | — | US | disclosed |
| EP-3549930-A1 | NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED | Hiroshima University (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3549930-A1 | NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED | Hiroshima University (JP) | 2019-10-09 | — | — | EP | disclosed |
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1673360-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| US-20050124676-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2005-06-09 | — | — | US | disclosed |
| WO-2005037812-A1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124676-A1 | EP4 receptor antagonists | PTGER4, PTGER3, NR4A3 | ALDH1A1 2257/4885NPC1 2821/4885RAB9A 4505/4885 |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER3, NR4A3 | ALDH1A1 2257/4885NPC1 2821/4885RAB9A 4505/4885 |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | PTGER4, PTGER3, NR4A3 | ALDH1A1 2241/4885NPC1 3071/4885RAB9A 4373/4885 |
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | PIN1, APC, GSKIP | ALDH1A1 3207/4885NPC1 71/4885RAB9A 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.